nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Uveitis—Erlotinib—pancreatic cancer	0.041	0.0503	CcSEcCtD
Metipranolol—Lacrimation—Irinotecan—pancreatic cancer	0.0174	0.0213	CcSEcCtD
Metipranolol—Lacrimation—Fluorouracil—pancreatic cancer	0.0166	0.0204	CcSEcCtD
Metipranolol—Blepharitis—Fluorouracil—pancreatic cancer	0.0159	0.0195	CcSEcCtD
Metipranolol—Lacrimation increased—Sunitinib—pancreatic cancer	0.0135	0.0165	CcSEcCtD
Metipranolol—Lacrimation—Docetaxel—pancreatic cancer	0.012	0.0147	CcSEcCtD
Metipranolol—Lacrimation increased—Irinotecan—pancreatic cancer	0.0111	0.0136	CcSEcCtD
Metipranolol—Arthritis—Tamoxifen—pancreatic cancer	0.0108	0.0133	CcSEcCtD
Metipranolol—Lacrimation increased—Fluorouracil—pancreatic cancer	0.0106	0.013	CcSEcCtD
Metipranolol—Photophobia—Fluorouracil—pancreatic cancer	0.00919	0.0113	CcSEcCtD
Metipranolol—Angina pectoris—Tamoxifen—pancreatic cancer	0.00885	0.0109	CcSEcCtD
Metipranolol—Bronchitis—Tamoxifen—pancreatic cancer	0.00874	0.0107	CcSEcCtD
Metipranolol—Lacrimation—Epirubicin—pancreatic cancer	0.0081	0.00995	CcSEcCtD
Metipranolol—Acute coronary syndrome—Tamoxifen—pancreatic cancer	0.00799	0.0098	CcSEcCtD
Metipranolol—Myocardial infarction—Tamoxifen—pancreatic cancer	0.00794	0.00975	CcSEcCtD
Metipranolol—Acute coronary syndrome—Erlotinib—pancreatic cancer	0.0079	0.0097	CcSEcCtD
Metipranolol—Myocardial infarction—Erlotinib—pancreatic cancer	0.00786	0.00965	CcSEcCtD
Metipranolol—Conjunctivitis—Erlotinib—pancreatic cancer	0.00779	0.00956	CcSEcCtD
Metipranolol—Lacrimation increased—Docetaxel—pancreatic cancer	0.00766	0.00941	CcSEcCtD
Metipranolol—Epistaxis—Erlotinib—pancreatic cancer	0.00756	0.00928	CcSEcCtD
Metipranolol—Lacrimation—Doxorubicin—pancreatic cancer	0.0075	0.0092	CcSEcCtD
Metipranolol—Bronchitis—Sunitinib—pancreatic cancer	0.00748	0.00919	CcSEcCtD
Metipranolol—Visual impairment—Tamoxifen—pancreatic cancer	0.00701	0.0086	CcSEcCtD
Metipranolol—Acute coronary syndrome—Sunitinib—pancreatic cancer	0.00684	0.0084	CcSEcCtD
Metipranolol—Epistaxis—Sunitinib—pancreatic cancer	0.00654	0.00803	CcSEcCtD
Metipranolol—Bradycardia—Sunitinib—pancreatic cancer	0.00634	0.00778	CcSEcCtD
Metipranolol—Angina pectoris—Irinotecan—pancreatic cancer	0.00624	0.00767	CcSEcCtD
Metipranolol—Angina pectoris—Fluorouracil—pancreatic cancer	0.00598	0.00734	CcSEcCtD
Metipranolol—Acute coronary syndrome—Irinotecan—pancreatic cancer	0.00563	0.00692	CcSEcCtD
Metipranolol—Myocardial infarction—Irinotecan—pancreatic cancer	0.0056	0.00688	CcSEcCtD
Metipranolol—Cough—Tamoxifen—pancreatic cancer	0.00552	0.00678	CcSEcCtD
Metipranolol—Acute coronary syndrome—Gemcitabine—pancreatic cancer	0.00549	0.00674	CcSEcCtD
Metipranolol—Hypertension—Tamoxifen—pancreatic cancer	0.00547	0.00671	CcSEcCtD
Metipranolol—Cough—Erlotinib—pancreatic cancer	0.00547	0.00671	CcSEcCtD
Metipranolol—Myocardial infarction—Gemcitabine—pancreatic cancer	0.00546	0.0067	CcSEcCtD
Metipranolol—Atrial fibrillation—Docetaxel—pancreatic cancer	0.00541	0.00664	CcSEcCtD
Metipranolol—Acute coronary syndrome—Fluorouracil—pancreatic cancer	0.0054	0.00662	CcSEcCtD
Metipranolol—Myalgia—Tamoxifen—pancreatic cancer	0.00539	0.00662	CcSEcCtD
Metipranolol—Anxiety—Tamoxifen—pancreatic cancer	0.00537	0.00659	CcSEcCtD
Metipranolol—Myocardial infarction—Fluorouracil—pancreatic cancer	0.00537	0.00659	CcSEcCtD
Metipranolol—Myalgia—Erlotinib—pancreatic cancer	0.00533	0.00655	CcSEcCtD
Metipranolol—Discomfort—Tamoxifen—pancreatic cancer	0.00533	0.00654	CcSEcCtD
Metipranolol—Conjunctivitis—Fluorouracil—pancreatic cancer	0.00532	0.00653	CcSEcCtD
Metipranolol—Anxiety—Erlotinib—pancreatic cancer	0.00531	0.00652	CcSEcCtD
Metipranolol—Bradycardia—Irinotecan—pancreatic cancer	0.00522	0.00641	CcSEcCtD
Metipranolol—Lacrimation increased—Epirubicin—pancreatic cancer	0.00517	0.00635	CcSEcCtD
Metipranolol—Oedema—Tamoxifen—pancreatic cancer	0.00517	0.00634	CcSEcCtD
Metipranolol—Epistaxis—Fluorouracil—pancreatic cancer	0.00516	0.00634	CcSEcCtD
Metipranolol—Rhinitis—Irinotecan—pancreatic cancer	0.00514	0.00632	CcSEcCtD
Metipranolol—Oedema—Erlotinib—pancreatic cancer	0.00511	0.00628	CcSEcCtD
Metipranolol—Rhinitis—Gemcitabine—pancreatic cancer	0.00501	0.00615	CcSEcCtD
Metipranolol—Visual impairment—Irinotecan—pancreatic cancer	0.00494	0.00607	CcSEcCtD
Metipranolol—Rhinitis—Fluorouracil—pancreatic cancer	0.00493	0.00605	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—pancreatic cancer	0.00478	0.00587	CcSEcCtD
Metipranolol—Cough—Sunitinib—pancreatic cancer	0.00473	0.00581	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00471	0.00578	CcSEcCtD
Metipranolol—Hypertension—Sunitinib—pancreatic cancer	0.00468	0.00575	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00466	0.00572	CcSEcCtD
Metipranolol—Myalgia—Sunitinib—pancreatic cancer	0.00462	0.00567	CcSEcCtD
Metipranolol—Dyspnoea—Tamoxifen—pancreatic cancer	0.00461	0.00566	CcSEcCtD
Metipranolol—Dyspnoea—Erlotinib—pancreatic cancer	0.00456	0.0056	CcSEcCtD
Metipranolol—Oedema—Sunitinib—pancreatic cancer	0.00443	0.00543	CcSEcCtD
Metipranolol—Angina pectoris—Docetaxel—pancreatic cancer	0.00432	0.0053	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—pancreatic cancer	0.00415	0.0051	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00403	0.00495	CcSEcCtD
Metipranolol—Vision blurred—Fluorouracil—pancreatic cancer	0.00403	0.00495	CcSEcCtD
Metipranolol—Dyspnoea—Sunitinib—pancreatic cancer	0.00395	0.00484	CcSEcCtD
Metipranolol—Cough—Irinotecan—pancreatic cancer	0.0039	0.00478	CcSEcCtD
Metipranolol—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.00389	0.00478	CcSEcCtD
Metipranolol—Myocardial infarction—Docetaxel—pancreatic cancer	0.00387	0.00475	CcSEcCtD
Metipranolol—Hypertension—Irinotecan—pancreatic cancer	0.00386	0.00473	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—pancreatic cancer	0.00384	0.00472	CcSEcCtD
Metipranolol—Conjunctivitis—Docetaxel—pancreatic cancer	0.00384	0.00471	CcSEcCtD
Metipranolol—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00381	0.00467	CcSEcCtD
Metipranolol—Cough—Gemcitabine—pancreatic cancer	0.0038	0.00466	CcSEcCtD
Metipranolol—Discomfort—Irinotecan—pancreatic cancer	0.00376	0.00461	CcSEcCtD
Metipranolol—Hypertension—Gemcitabine—pancreatic cancer	0.00376	0.00461	CcSEcCtD
Metipranolol—Epistaxis—Docetaxel—pancreatic cancer	0.00373	0.00458	CcSEcCtD
Metipranolol—Asthenia—Tamoxifen—pancreatic cancer	0.00371	0.00455	CcSEcCtD
Metipranolol—Myalgia—Gemcitabine—pancreatic cancer	0.0037	0.00455	CcSEcCtD
Metipranolol—Asthenia—Erlotinib—pancreatic cancer	0.00367	0.0045	CcSEcCtD
Metipranolol—Discomfort—Gemcitabine—pancreatic cancer	0.00366	0.00449	CcSEcCtD
Metipranolol—Oedema—Irinotecan—pancreatic cancer	0.00365	0.00448	CcSEcCtD
Metipranolol—Myalgia—Fluorouracil—pancreatic cancer	0.00364	0.00447	CcSEcCtD
Metipranolol—Discomfort—Fluorouracil—pancreatic cancer	0.0036	0.00442	CcSEcCtD
Metipranolol—Rhinitis—Docetaxel—pancreatic cancer	0.00356	0.00437	CcSEcCtD
Metipranolol—Oedema—Gemcitabine—pancreatic cancer	0.00355	0.00436	CcSEcCtD
Metipranolol—Oedema—Fluorouracil—pancreatic cancer	0.00349	0.00429	CcSEcCtD
Metipranolol—Visual impairment—Docetaxel—pancreatic cancer	0.00342	0.0042	CcSEcCtD
Metipranolol—Dizziness—Tamoxifen—pancreatic cancer	0.00342	0.00419	CcSEcCtD
Metipranolol—Dizziness—Erlotinib—pancreatic cancer	0.00338	0.00415	CcSEcCtD
Metipranolol—Hypersensitivity—Sunitinib—pancreatic cancer	0.00326	0.004	CcSEcCtD
Metipranolol—Rash—Tamoxifen—pancreatic cancer	0.00326	0.004	CcSEcCtD
Metipranolol—Dermatitis—Tamoxifen—pancreatic cancer	0.00325	0.004	CcSEcCtD
Metipranolol—Dyspnoea—Irinotecan—pancreatic cancer	0.00325	0.00399	CcSEcCtD
Metipranolol—Somnolence—Irinotecan—pancreatic cancer	0.00324	0.00398	CcSEcCtD
Metipranolol—Headache—Tamoxifen—pancreatic cancer	0.00324	0.00397	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00324	0.00397	CcSEcCtD
Metipranolol—Rash—Erlotinib—pancreatic cancer	0.00322	0.00396	CcSEcCtD
Metipranolol—Dermatitis—Erlotinib—pancreatic cancer	0.00322	0.00395	CcSEcCtD
Metipranolol—Headache—Erlotinib—pancreatic cancer	0.0032	0.00393	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00318	0.00391	CcSEcCtD
Metipranolol—Asthenia—Sunitinib—pancreatic cancer	0.00318	0.0039	CcSEcCtD
Metipranolol—Dyspnoea—Gemcitabine—pancreatic cancer	0.00317	0.00389	CcSEcCtD
Metipranolol—Somnolence—Gemcitabine—pancreatic cancer	0.00316	0.00388	CcSEcCtD
Metipranolol—Dyspnoea—Fluorouracil—pancreatic cancer	0.00311	0.00382	CcSEcCtD
Metipranolol—Somnolence—Fluorouracil—pancreatic cancer	0.0031	0.00381	CcSEcCtD
Metipranolol—Nausea—Tamoxifen—pancreatic cancer	0.00307	0.00377	CcSEcCtD
Metipranolol—Nausea—Erlotinib—pancreatic cancer	0.00304	0.00373	CcSEcCtD
Metipranolol—Dizziness—Sunitinib—pancreatic cancer	0.00293	0.00359	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—pancreatic cancer	0.00291	0.00357	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—pancreatic cancer	0.00287	0.00353	CcSEcCtD
Metipranolol—Rash—Sunitinib—pancreatic cancer	0.00279	0.00343	CcSEcCtD
Metipranolol—Dermatitis—Sunitinib—pancreatic cancer	0.00279	0.00342	CcSEcCtD
Metipranolol—Headache—Sunitinib—pancreatic cancer	0.00277	0.0034	CcSEcCtD
Metipranolol—Palpitations—Docetaxel—pancreatic cancer	0.00273	0.00335	CcSEcCtD
Metipranolol—Cough—Docetaxel—pancreatic cancer	0.00269	0.00331	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—pancreatic cancer	0.00269	0.00331	CcSEcCtD
Metipranolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.00269	0.0033	CcSEcCtD
Metipranolol—Hypertension—Docetaxel—pancreatic cancer	0.00267	0.00327	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—pancreatic cancer	0.00266	0.00327	CcSEcCtD
Metipranolol—Myalgia—Docetaxel—pancreatic cancer	0.00263	0.00323	CcSEcCtD
Metipranolol—Nausea—Sunitinib—pancreatic cancer	0.00263	0.00323	CcSEcCtD
Metipranolol—Asthenia—Irinotecan—pancreatic cancer	0.00262	0.00321	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.00259	0.00318	CcSEcCtD
Metipranolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00257	0.00316	CcSEcCtD
Metipranolol—Asthenia—Gemcitabine—pancreatic cancer	0.00255	0.00313	CcSEcCtD
Metipranolol—Oedema—Docetaxel—pancreatic cancer	0.00252	0.00309	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—pancreatic cancer	0.00251	0.00309	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—pancreatic cancer	0.00244	0.00299	CcSEcCtD
Metipranolol—Dizziness—Irinotecan—pancreatic cancer	0.00241	0.00296	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—pancreatic cancer	0.0024	0.00294	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.0024	0.00294	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—pancreatic cancer	0.00233	0.00286	CcSEcCtD
Metipranolol—Dizziness—Fluorouracil—pancreatic cancer	0.00231	0.00283	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—pancreatic cancer	0.00231	0.00283	CcSEcCtD
Metipranolol—Rash—Irinotecan—pancreatic cancer	0.0023	0.00282	CcSEcCtD
Metipranolol—Dermatitis—Irinotecan—pancreatic cancer	0.0023	0.00282	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.0023	0.00282	CcSEcCtD
Metipranolol—Headache—Irinotecan—pancreatic cancer	0.00228	0.0028	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—pancreatic cancer	0.00225	0.00277	CcSEcCtD
Metipranolol—Dyspnoea—Docetaxel—pancreatic cancer	0.00225	0.00276	CcSEcCtD
Metipranolol—Somnolence—Docetaxel—pancreatic cancer	0.00224	0.00275	CcSEcCtD
Metipranolol—Rash—Gemcitabine—pancreatic cancer	0.00224	0.00275	CcSEcCtD
Metipranolol—Dermatitis—Gemcitabine—pancreatic cancer	0.00224	0.00275	CcSEcCtD
Metipranolol—Headache—Gemcitabine—pancreatic cancer	0.00222	0.00273	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—pancreatic cancer	0.00222	0.00272	CcSEcCtD
Metipranolol—Rash—Fluorouracil—pancreatic cancer	0.0022	0.0027	CcSEcCtD
Metipranolol—Dermatitis—Fluorouracil—pancreatic cancer	0.0022	0.0027	CcSEcCtD
Metipranolol—Headache—Fluorouracil—pancreatic cancer	0.00219	0.00269	CcSEcCtD
Metipranolol—Nausea—Irinotecan—pancreatic cancer	0.00217	0.00266	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—pancreatic cancer	0.00213	0.00262	CcSEcCtD
Metipranolol—Nausea—Gemcitabine—pancreatic cancer	0.00211	0.00259	CcSEcCtD
Metipranolol—Nausea—Fluorouracil—pancreatic cancer	0.00207	0.00255	CcSEcCtD
Metipranolol—Tension—Epirubicin—pancreatic cancer	0.00204	0.00251	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—pancreatic cancer	0.00202	0.00248	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—pancreatic cancer	0.00196	0.00241	CcSEcCtD
Metipranolol—Tension—Doxorubicin—pancreatic cancer	0.00189	0.00232	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—pancreatic cancer	0.00187	0.0023	CcSEcCtD
Metipranolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.00186	0.00228	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—pancreatic cancer	0.00184	0.00226	CcSEcCtD
Metipranolol—Cough—Epirubicin—pancreatic cancer	0.00182	0.00223	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—pancreatic cancer	0.00182	0.00223	CcSEcCtD
Metipranolol—Asthenia—Docetaxel—pancreatic cancer	0.00181	0.00222	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—pancreatic cancer	0.0018	0.00221	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—pancreatic cancer	0.00177	0.00218	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—pancreatic cancer	0.00177	0.00217	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—pancreatic cancer	0.00175	0.00215	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—pancreatic cancer	0.0017	0.00209	CcSEcCtD
Metipranolol—Oedema—Epirubicin—pancreatic cancer	0.0017	0.00209	CcSEcCtD
Metipranolol—Cough—Doxorubicin—pancreatic cancer	0.00168	0.00206	CcSEcCtD
Metipranolol—Dizziness—Docetaxel—pancreatic cancer	0.00167	0.00205	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—pancreatic cancer	0.00166	0.00204	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—pancreatic cancer	0.00164	0.00201	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—pancreatic cancer	0.00163	0.00201	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—pancreatic cancer	0.00162	0.00199	CcSEcCtD
Metipranolol—Rash—Docetaxel—pancreatic cancer	0.00159	0.00195	CcSEcCtD
Metipranolol—Dermatitis—Docetaxel—pancreatic cancer	0.00159	0.00195	CcSEcCtD
Metipranolol—Headache—Docetaxel—pancreatic cancer	0.00158	0.00194	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—pancreatic cancer	0.00157	0.00193	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00155	0.0019	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—pancreatic cancer	0.00152	0.00186	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—pancreatic cancer	0.00151	0.00186	CcSEcCtD
Metipranolol—Nausea—Docetaxel—pancreatic cancer	0.0015	0.00184	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00143	0.00176	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.0014	0.00172	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—pancreatic cancer	0.0014	0.00172	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.00125	0.00154	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—pancreatic cancer	0.00122	0.0015	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00116	0.00142	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—pancreatic cancer	0.00113	0.00139	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—pancreatic cancer	0.00112	0.00138	CcSEcCtD
Metipranolol—Rash—Epirubicin—pancreatic cancer	0.00107	0.00132	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—pancreatic cancer	0.00107	0.00131	CcSEcCtD
Metipranolol—Headache—Epirubicin—pancreatic cancer	0.00106	0.00131	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—pancreatic cancer	0.00104	0.00128	CcSEcCtD
Metipranolol—Nausea—Epirubicin—pancreatic cancer	0.00101	0.00124	CcSEcCtD
Metipranolol—Rash—Doxorubicin—pancreatic cancer	0.000992	0.00122	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—pancreatic cancer	0.000991	0.00122	CcSEcCtD
Metipranolol—Headache—Doxorubicin—pancreatic cancer	0.000985	0.00121	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—pancreatic cancer	0.000934	0.00115	CcSEcCtD
Metipranolol—ADRB1—Signaling Pathways—GDI1—pancreatic cancer	0.000606	0.00327	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000606	0.00327	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000594	0.0032	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GDI1—pancreatic cancer	0.000593	0.0032	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GDI2—pancreatic cancer	0.000593	0.0032	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PPY—pancreatic cancer	0.000582	0.00314	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000581	0.00313	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—SST—pancreatic cancer	0.000576	0.0031	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000571	0.00308	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PPY—pancreatic cancer	0.000569	0.00307	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—SST—pancreatic cancer	0.000563	0.00304	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SSTR3—pancreatic cancer	0.000562	0.00303	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000559	0.00301	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000552	0.00298	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SSTR3—pancreatic cancer	0.00055	0.00297	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00054	0.00291	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SSTR1—pancreatic cancer	0.000539	0.00291	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CNR1—pancreatic cancer	0.000531	0.00286	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PPY—pancreatic cancer	0.000529	0.00285	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SSTR1—pancreatic cancer	0.000527	0.00284	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CNR1—pancreatic cancer	0.00052	0.0028	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000519	0.0028	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PPY—pancreatic cancer	0.000517	0.00279	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—GCG—pancreatic cancer	0.000513	0.00277	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SSTR2—pancreatic cancer	0.000508	0.00274	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—GCG—pancreatic cancer	0.000502	0.00271	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCKBR—pancreatic cancer	0.000501	0.0027	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCKBR—pancreatic cancer	0.00049	0.00264	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—AGTR1—pancreatic cancer	0.000489	0.00264	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—AGTR1—pancreatic cancer	0.000479	0.00258	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GAST—pancreatic cancer	0.000475	0.00256	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GAST—pancreatic cancer	0.000464	0.0025	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—SCT—pancreatic cancer	0.00045	0.00243	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—SCT—pancreatic cancer	0.00044	0.00237	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GAST—pancreatic cancer	0.000431	0.00232	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCK—pancreatic cancer	0.000429	0.00231	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GAST—pancreatic cancer	0.000422	0.00227	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCK—pancreatic cancer	0.00042	0.00226	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000418	0.00225	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000418	0.00225	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000411	0.00222	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CNR2—pancreatic cancer	0.000409	0.00221	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000409	0.00221	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SCT—pancreatic cancer	0.000409	0.0022	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000402	0.00217	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SCT—pancreatic cancer	0.0004	0.00215	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRLHR—pancreatic cancer	0.000391	0.00211	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCK—pancreatic cancer	0.00039	0.0021	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRLHR—pancreatic cancer	0.000382	0.00206	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCK—pancreatic cancer	0.000381	0.00206	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CNR2—pancreatic cancer	0.00038	0.00205	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GLP1R—pancreatic cancer	0.00038	0.00205	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000374	0.00201	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CNR2—pancreatic cancer	0.000372	0.002	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GLP1R—pancreatic cancer	0.000372	0.002	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IAPP—pancreatic cancer	0.00037	0.002	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000367	0.00198	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000367	0.00198	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCKAR—pancreatic cancer	0.000365	0.00197	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IAPP—pancreatic cancer	0.000362	0.00195	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ZNRF3—pancreatic cancer	0.000359	0.00194	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ACVR1B—pancreatic cancer	0.000359	0.00194	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000356	0.00192	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000348	0.00188	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SHH—pancreatic cancer	0.000341	0.00184	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IAPP—pancreatic cancer	0.000336	0.00181	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SHH—pancreatic cancer	0.000333	0.0018	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SSTR3—pancreatic cancer	0.000332	0.00179	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—DTX1—pancreatic cancer	0.000332	0.00179	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IAPP—pancreatic cancer	0.000329	0.00177	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—SST—pancreatic cancer	0.000325	0.00175	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SSTR3—pancreatic cancer	0.000325	0.00175	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—DTX1—pancreatic cancer	0.000325	0.00175	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000323	0.00174	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000323	0.00174	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SSTR1—pancreatic cancer	0.000318	0.00172	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—SST—pancreatic cancer	0.000318	0.00172	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PTHLH—pancreatic cancer	0.000316	0.0017	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PTCH1—pancreatic cancer	0.000316	0.0017	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PPY—pancreatic cancer	0.000312	0.00168	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SSTR1—pancreatic cancer	0.000311	0.00168	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SSTR2—pancreatic cancer	0.000307	0.00165	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PPY—pancreatic cancer	0.000305	0.00165	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CNR1—pancreatic cancer	0.0003	0.00162	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SSTR2—pancreatic cancer	0.0003	0.00162	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCKBR—pancreatic cancer	0.000296	0.0016	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—SST—pancreatic cancer	0.000295	0.00159	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000294	0.00159	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CNR1—pancreatic cancer	0.000294	0.00158	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	0.00029	0.00156	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	0.00029	0.00156	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	0.000289	0.00156	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000288	0.00155	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	0.000284	0.00153	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	0.000278	0.0015	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	0.000278	0.0015	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000277	0.00149	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	0.000273	0.00147	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	0.000272	0.00147	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	0.000272	0.00147	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	0.000271	0.00146	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000271	0.00146	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000271	0.00146	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	0.000267	0.00144	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	0.000265	0.00143	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000265	0.00143	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	0.000263	0.00142	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	0.000261	0.00141	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	0.000258	0.00139	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	0.000255	0.00137	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	0.000255	0.00137	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	0.000251	0.00135	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	0.000249	0.00134	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	0.000246	0.00132	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	0.000241	0.0013	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	0.000241	0.0013	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	0.000236	0.00127	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	0.000236	0.00127	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	0.00023	0.00124	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	0.000225	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	0.000224	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	0.000224	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	0.000224	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	0.000221	0.00119	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	0.000219	0.00118	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	0.000219	0.00118	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	0.000219	0.00118	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	0.000216	0.00116	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	0.000214	0.00115	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	0.000211	0.00114	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	0.000209	0.00113	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	0.000206	0.00111	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	0.000201	0.00108	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	0.0002	0.00108	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	0.000199	0.00107	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	0.000197	0.00106	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	0.000196	0.00105	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	0.000194	0.00105	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	0.000191	0.00103	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	0.000191	0.00103	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	0.000187	0.00101	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	0.000187	0.00101	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	0.000174	0.000941	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000172	0.000928	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	0.000171	0.000921	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	0.000171	0.00092	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	0.00017	0.000917	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000168	0.000908	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	0.000167	0.000901	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	0.000166	0.000897	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	0.000161	0.000868	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	0.000158	0.000849	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000156	0.000843	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	0.000156	0.000838	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000153	0.000824	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	0.000152	0.00082	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000151	0.000816	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	0.000148	0.0008	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000148	0.000798	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	0.000146	0.000788	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	0.000145	0.000782	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	0.000143	0.000771	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000137	0.000741	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000134	0.000725	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000132	0.000711	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000129	0.000695	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	0.000128	0.00069	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000127	0.000683	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	0.000125	0.000675	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	0.000125	0.000674	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000124	0.000668	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	0.000122	0.000659	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.00012	0.000646	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000117	0.000632	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000115	0.00062	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	0.000113	0.000607	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	0.00011	0.000591	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	0.000107	0.000578	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	0.000105	0.000565	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	0.000105	0.000564	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	0.000102	0.000553	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	0.000102	0.000552	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	0.000102	0.000551	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	0.0001	0.00054	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	0.0001	0.000539	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	9.8e-05	0.000529	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	9.53e-05	0.000514	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	9.44e-05	0.000509	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	9.32e-05	0.000503	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	9.23e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	9.23e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	9.23e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	9.12e-05	0.000492	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	9.03e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	9.03e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	8.93e-05	0.000481	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	8.41e-05	0.000453	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	8.23e-05	0.000444	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	8.11e-05	0.000438	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.04e-05	0.000433	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	7.94e-05	0.000428	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	7.94e-05	0.000428	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.86e-05	0.000424	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	7.77e-05	0.000419	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.3e-05	0.000394	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.14e-05	0.000385	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	7.07e-05	0.000381	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	6.92e-05	0.000373	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	6.8e-05	0.000366	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	6.75e-05	0.000364	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	6.65e-05	0.000359	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	6.61e-05	0.000356	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	6.57e-05	0.000354	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	6.51e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	6.42e-05	0.000346	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	6.36e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	6.33e-05	0.000341	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	6.27e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	6.19e-05	0.000334	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	6.15e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	6.13e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	6.11e-05	0.00033	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	6.01e-05	0.000324	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	5.98e-05	0.000322	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	5.96e-05	0.000322	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	5.83e-05	0.000315	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	5.67e-05	0.000306	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	5.54e-05	0.000299	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	5.52e-05	0.000298	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	5.47e-05	0.000295	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	5.45e-05	0.000294	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	5.4e-05	0.000291	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	5.35e-05	0.000288	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	5.33e-05	0.000288	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	5.08e-05	0.000274	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	5.07e-05	0.000273	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.97e-05	0.000268	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.97e-05	0.000268	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.96e-05	0.000267	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.86e-05	0.000262	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	4.69e-05	0.000253	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	4.59e-05	0.000248	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	4.31e-05	0.000232	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	4.22e-05	0.000227	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	4.17e-05	0.000225	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	4.08e-05	0.00022	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.99e-05	0.000215	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.9e-05	0.00021	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	3.52e-05	0.00019	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	3.45e-05	0.000186	CbGpPWpGaD
